Effects of legumain as a potential prognostic factor on gastric cancers

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Li, Na ^a   Liu, Qiaoling ^b   Su, Qi ^a   Wei, Chongyang ^b   Lan, Bin ^a   Wang, Jianyong ^b   Bao, Guoqing ^a   Yan, Fei ^c   Yu, Ying ^b   Peng, Baowei ^b   Qiu, Ju ^d   Yan, Xiangming ^b   Zhang, Sheng ^e   Guo, Fang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI ADVANCED RESEARCH INSTITUTE   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Asparaginyl endopeptidase inhibitor; Gastric cancer; Legumain; Metastasis; Prognosis

Indexed keywords

ASPARAGINYL ENDOPEPTIDASE INHIBITOR; COMPLEMENTARY DNA; ENZYME INHIBITOR; LEGUMAIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; STOMACH CANCER; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR GROWTH; WOUND HEALING; ADENOCARCINOMA; ANIMAL; CARCINOGENESIS; CELL MOTION; GENETICS; NUDE MOUSE; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CYSTEINE ENDOPEPTIDASES; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84878419479     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0621-9     Document Type: Article

References (24)

1. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8:437-47.
2. Catalano V, Labianca R, Beretta GD, et al. Gastric Cancer. Crit Rev Oncol Hematol. 2005;54:209-41.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. 2012; 62(1):10-29.
4. Lim L, Michael M, Mann GB, et al. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23:6220-32.
5. Chen JM, Dando PM, Rawlings ND, et al. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem. 1997;272:8090-8.
6. Chen JM, Dando PM, Stevens RA, et al. Cloning and expression of mouse legumain, a lysosomal endopeptidase. Biochem J. 1998;335:111-7.
7. Shirahama-Noda K, Yamamoto A, Sugihara K, et al. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem. 2003; 278:33194-9.
8. Smith R, Johansen HT, Nilsen H, et al. Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M. Biochimie. 2012;94:2590-9.
9. Morita Y, Araki H, Sugimoto T, et al. Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells. FEBS Lett. 2007;581:1417-24.
10. Chen JM, Fortunato M, Stevens RA, Barrett AJ. Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem. 2001;382:777-83.
11. Liu C, Sun C, Huang H, et al. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003;63: 2957-64.
12. Murthy RV, Arbman G, Gao J, et al. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 2005;11:2293-9.
13. Gawenda J, Traub F, Lück HJ, et al. Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 2007;102:1-6.
14. Wang L, Chen S, Zhang M, et al. Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem. 2012;113:2679-86.
15. Wu W, Luo Y, Sun C, et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drugresistant neoplasms. Cancer Res. 2006;66:970-80.
16. Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006;116:2132-41.
17. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2006;141:52-67.
18. Kubben FJ, Sier CF, van Duijn W, et al. Matrix metalloproteinase- 2 is a consistent prognostic factor in gastric cancer. British J Cancer. 2006;94:1035-40.
19. Hsu FD, Nielsen TO, Alkushi A, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol. 2002;15:1374-80.
20. Yan F, Cao XX, Jiang HX, et al. A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer. J Med Chem. 2010;53: 5502-10.
21. Powers JC, James KE, Gotz MG, Caffrey CR, Hansell E, Carter W, et al. Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (Asparaginyl endopeptidases). Biol Chem. 2003;384(12):1613-8.
22. Wu BH, Yin J, Texier C, Roussel M. Blastocystis legumain is localized on the cell surface, and specific inhibition of its activity implicates a pro-survival role for the enzyme. J Biol Chem. 2010; 285(3):1790-8.
23. Wang L, Heidt DG, Lee CJ, et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and b-catenin stabilization. Cancer Cell. 2009;15:207-19.
24. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904-12.